GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

The asset in question is GSK’s 72.5% stake in its Indian subsidiary GlaxoSmithKline Consumer Healthcare, famous for the malted drink. The Indian division also makes the chocolate-flavoured drink ...

Dr. Ali Sherif normally gives about 50 doses of the measles vaccine to children each month at his clinic in Hobbs, New Mexico ...

Centrum, a trusted name in comprehensive multivitamin support, today announced the expansion of its product portfolio with the launch of Centrum Recharge, a new entrant into the competitive Energy ...

Dr. Kiran Mahasuar, Asst Professor at IMT Ghaziabad, writes why branded generics may still dominate volumes, but the real ...

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

France, long recognized as a global leader in cosmetic innovation and export, plays a pivotal role in the retinoid market. The French retinoid industry is growing at the fastest pace in Europe, with a ...

Zaven Boyrazian explores three FTSE 100 shares with impressive track records of navigating through even the worst economic climates. The post 3 FTSE 100 shares to consider buying in a recession ...

Karnataka: Syngene International Limited, a listed subsidiary of Biocon Limited, has announced the resignation of ...

The farewell to Sino-American SK signals a new chapter for UK businesses. China is no longer simply a joint venture “test ...

The Jakarta event brought together marketing leaders to discuss the future of the industry, from AI and DTC to consumer ...